Cargando…
2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
BACKGROUND: The quadrivalent meningococcal ACWY polysaccharide tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix) is licensed in various countries to prevent disease caused by meningococcal serogroups A, C, W, and Y. In a previous study (NCT00464815), subjects aged 11‒17 years received a primar...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810409/ http://dx.doi.org/10.1093/ofid/ofz360.2406 |
_version_ | 1783462247290372096 |
---|---|
author | Quiambao, Beatriz Peyrani, Paula Webber, Chris Van Der Wielen, Marie Bianco, Veronique Perez, John L Cutler, Mark W Li, Ping |
author_facet | Quiambao, Beatriz Peyrani, Paula Webber, Chris Van Der Wielen, Marie Bianco, Veronique Perez, John L Cutler, Mark W Li, Ping |
author_sort | Quiambao, Beatriz |
collection | PubMed |
description | BACKGROUND: The quadrivalent meningococcal ACWY polysaccharide tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix) is licensed in various countries to prevent disease caused by meningococcal serogroups A, C, W, and Y. In a previous study (NCT00464815), subjects aged 11‒17 years received a primary dose of MenACWY-TT or a quadrivalent polysaccharide vaccine (MenACWY-PS). Here, we report the long-term antibody persistence of the primary dose and the immunogenicity and safety of a booster dose given 10 years after primary vaccination of subjects. METHODS: Participants were enrolled from the Philippines and received a booster dose of MenACWY-TT at 10 years postvaccination. Antibody persistence 10 years postprimary vaccination and immunogenicity 1 month after the booster dose were evaluated by serum bactericidal activity assays using rabbit complement (rSBA) to assess the percentages of subjects with titers ≥ 1:8 and ≥ 1:128 and geometric mean titers (GMTs) for each serogroup. Safety was assessed for the booster dose. RESULTS: Of 229 subjects enrolled in this extension study, 169 and 58 subjects in the MenACWY-TT and MenACWY-PS groups, respectively, completed the booster phase. The percentages of primary MenACWY-TT recipients with prebooster rSBA titers ≥ 1:8 and ≥ 1:128 at year 10 ranged from 71.6%‒90.7% and 64.8%‒85.2% for all serogroups, respectively, compared with 43.1%‒82.4% and 25.5%‒76.5% of primary MenACWY-PS recipients; rSBA GMTs for all serogroups were higher in the MenACWY-TT group than in the MenACWY-PS group at year 10. For the MenACWY-TT and MenACWY-PS groups, respectively, the MenACWY-TT booster dose elicited rSBA titers ≥ 1:8 in 100% and ≥ 98.0% of subjects (figure); 100% and ≥ 96.1% of all subjects had titers ≥ 1:128. For all serogroups, rSBA GMTs at 1 month after the booster dose were higher than before the booster dose. No new safety signals were observed during the booster phase. CONCLUSION: Functional antibody responses elicited by MenACWY-TT persisted 10 years after primary vaccination; the booster dose was well tolerated and elicited robust immune responses. CLINICALTRIALS.GOV: NCT03189745, EudraCT # 2013-001512-29. Funded by Pfizer. [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6810409 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68104092019-10-28 2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS Quiambao, Beatriz Peyrani, Paula Webber, Chris Van Der Wielen, Marie Bianco, Veronique Perez, John L Cutler, Mark W Li, Ping Open Forum Infect Dis Abstracts BACKGROUND: The quadrivalent meningococcal ACWY polysaccharide tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix) is licensed in various countries to prevent disease caused by meningococcal serogroups A, C, W, and Y. In a previous study (NCT00464815), subjects aged 11‒17 years received a primary dose of MenACWY-TT or a quadrivalent polysaccharide vaccine (MenACWY-PS). Here, we report the long-term antibody persistence of the primary dose and the immunogenicity and safety of a booster dose given 10 years after primary vaccination of subjects. METHODS: Participants were enrolled from the Philippines and received a booster dose of MenACWY-TT at 10 years postvaccination. Antibody persistence 10 years postprimary vaccination and immunogenicity 1 month after the booster dose were evaluated by serum bactericidal activity assays using rabbit complement (rSBA) to assess the percentages of subjects with titers ≥ 1:8 and ≥ 1:128 and geometric mean titers (GMTs) for each serogroup. Safety was assessed for the booster dose. RESULTS: Of 229 subjects enrolled in this extension study, 169 and 58 subjects in the MenACWY-TT and MenACWY-PS groups, respectively, completed the booster phase. The percentages of primary MenACWY-TT recipients with prebooster rSBA titers ≥ 1:8 and ≥ 1:128 at year 10 ranged from 71.6%‒90.7% and 64.8%‒85.2% for all serogroups, respectively, compared with 43.1%‒82.4% and 25.5%‒76.5% of primary MenACWY-PS recipients; rSBA GMTs for all serogroups were higher in the MenACWY-TT group than in the MenACWY-PS group at year 10. For the MenACWY-TT and MenACWY-PS groups, respectively, the MenACWY-TT booster dose elicited rSBA titers ≥ 1:8 in 100% and ≥ 98.0% of subjects (figure); 100% and ≥ 96.1% of all subjects had titers ≥ 1:128. For all serogroups, rSBA GMTs at 1 month after the booster dose were higher than before the booster dose. No new safety signals were observed during the booster phase. CONCLUSION: Functional antibody responses elicited by MenACWY-TT persisted 10 years after primary vaccination; the booster dose was well tolerated and elicited robust immune responses. CLINICALTRIALS.GOV: NCT03189745, EudraCT # 2013-001512-29. Funded by Pfizer. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810409/ http://dx.doi.org/10.1093/ofid/ofz360.2406 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Quiambao, Beatriz Peyrani, Paula Webber, Chris Van Der Wielen, Marie Bianco, Veronique Perez, John L Cutler, Mark W Li, Ping 2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS |
title | 2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS |
title_full | 2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS |
title_fullStr | 2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS |
title_full_unstemmed | 2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS |
title_short | 2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS |
title_sort | 2722 b. efficacy and safety of a booster dose of the menacwy-tt vaccine administered 10 years after primary vaccination with menacwy-tt or menacwy-ps |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810409/ http://dx.doi.org/10.1093/ofid/ofz360.2406 |
work_keys_str_mv | AT quiambaobeatriz 2722befficacyandsafetyofaboosterdoseofthemenacwyttvaccineadministered10yearsafterprimaryvaccinationwithmenacwyttormenacwyps AT peyranipaula 2722befficacyandsafetyofaboosterdoseofthemenacwyttvaccineadministered10yearsafterprimaryvaccinationwithmenacwyttormenacwyps AT webberchris 2722befficacyandsafetyofaboosterdoseofthemenacwyttvaccineadministered10yearsafterprimaryvaccinationwithmenacwyttormenacwyps AT vanderwielenmarie 2722befficacyandsafetyofaboosterdoseofthemenacwyttvaccineadministered10yearsafterprimaryvaccinationwithmenacwyttormenacwyps AT biancoveronique 2722befficacyandsafetyofaboosterdoseofthemenacwyttvaccineadministered10yearsafterprimaryvaccinationwithmenacwyttormenacwyps AT perezjohnl 2722befficacyandsafetyofaboosterdoseofthemenacwyttvaccineadministered10yearsafterprimaryvaccinationwithmenacwyttormenacwyps AT cutlermarkw 2722befficacyandsafetyofaboosterdoseofthemenacwyttvaccineadministered10yearsafterprimaryvaccinationwithmenacwyttormenacwyps AT liping 2722befficacyandsafetyofaboosterdoseofthemenacwyttvaccineadministered10yearsafterprimaryvaccinationwithmenacwyttormenacwyps |